Anti-programmed death-1 (anti -programmed death-1,PD-1) antibodies and their ligand, PD-L1 antibodies, have shown antitumor efficacy in a variety of cancers, of which, pembrolizumab has been approved as a third-line treatment for PD-L1-expressing advanced GC [9]. Here, RPL17 is linked to gastric cancer.